Elliott M. Levy, M.D., is senior vice president, Global Development, responsible for the clinical development of Amgen’s pipeline.

Before joining Amgen, Levy served as senior vice president and head of Specialty Development at Bristol-Myers Squibb (BMS). Prior to that role, he held the position of senior vice president of Global Pharmacovigilance and Epidemiology. Levy joined BMS in 1997 and during his 17 years at the company, he held a range of senior positions in cardiovascular clinical development, immunoscience clinical research, and global clinical research operations.

Prior to BMS, Levy was a member of the Renal Division at Brigham and Women's Hospital in Boston, Massachusetts, where he was an investigator in federally sponsored outcomes research as well as industry-sponsored clinical trials.

Levy is a graduate of the Yale School of Medicine, where he was chief medical resident and trained in internal medicine and nephrology. He completed fellowship training in clinical research through the Robert Wood Johnson Clinical Scholars Program at Yale.

Michael A. Kelly is senior vice president, Global Business Services. Prior to assuming this role, Kelly was vice president, Global Business Services and served as Amgen’s acting chief financial officer. He has held several other leadership roles including vice president, Finance; vice president, Commercial Operations; vice president, Finance, Amgen-Astellas Joint Venture Lead; vice president, Finance and chief financial officer International Commercial Operations; acting chief financial officer; vice president, Corporate Planning and Control and chief accounting officer; and vice president, Finance for Process Development, Operations and Quality.

Prior to joining Amgen in 2003, Kelly was vice president, Finance and chief financial officer at Tanox, Inc., served as corporate controller at Biogen, Inc. and held positions of increasing responsibility in finance at Monsanto Life Sciences Company, including chief financial officer of its NutraSweet Company subsidiary.

Kelly holds a bachelor’s degree in Business Administration from Florida A&M University.

Dr. Alexander Kamb is senior vice president, Discovery Research. In 2006, Kamb joined Amgen to direct Oncology Research at their South San Francisco site. He took over the leadership of the Neuroscience Therapeutic Area and was promoted to vice president, Research, and was given the remit to build a specialized department within Amgen Research (Genome Analysis Unit) focused on cross-disease-area applications of next-generation sequencing.

Prior to joining Amgen, Kamb worked in the biotechnology field specializing in the genetics of cancer, then in the Pharmaceutical sector where he led the Novartis Oncology Research Group.

Kamb received his A.B. from Harvard University and his Ph.D. from Caltech after a postdoctoral fellowship at UCSF.

Raymond C. Jordan joined Amgen as senior vice president, Corporate Affairs, in October 2012. In this role, Jordan is responsible for strategic communications across Amgen, including internal and external communications, issues management, and philanthropy.

Prior to joining Amgen, Jordan served as vice president of Public Affairs and Corporate Communication for Johnson & Johnson. He joined the company in 2003 as vice president, Group Communications, where he was focused on strategic communications for the Medical Devices and Diagnostics Group until he was appointed chief communication officer in 2004, ultimately overseeing the public affairs and corporate communications for more than 250 operating companies in 60 countries. Prior to Johnson & Johnson, Jordan was vice president of Communications and Information for Pfizer, where he held a range of positions over the course of 17 years. Earlier in his career, he was a reporter for a regional daily newspaper, held positions with Bristol-Myers and Dun & Bradstreet, and was cofounder of a management consulting firm.

Throughout the years, Jordan has also served the industry as chair of PhRMA’s Public Affairs section and the National Pharmaceutical Council’s User Group, and he has served as a member of the board of directors of the Foundation for American Communications, the board of trustees of the Institute for Public Relations, and the Seminar Committee, as well as a board member of the Arthur W. Page Society.

He is a graduate of Yale University and earned an MBA in marketing and finance from Columbia University.

Anthony C. Hooper is executive vice president, Global Commercial Operations for Amgen. In this role, he is responsible for ensuring Amgen’s innovative medicines reach patients, payers and physicians around the world.

With a successful biopharmaceutical career spanning more than 30 years, Hooper is a seasoned international executive with experience running biopharmaceutical businesses in five countries on four continents.

Prior to joining Amgen in October 2011, Hooper spent more than 15 years at Bristol-Myers Squibb Company. His last role there was senior vice president, Global Commercial Operations and president of the company’s $15 billion pharmaceutical business in the Americas, Japan and Intercontinental regions. Hooper was also assistant vice president of Global Marketing for Wyeth Laboratories. He also worked at Lederle International in New Jersey, where he led the international marketing group.

Hooper earned law and MBA degrees from the University of South Africa.

Rolf K. Hoffmann joined Amgen Europe GmbH in 2004 as senior vice president of Amgen Europe. In 2005, he assumed responsibility for all commercial operations outside the United States and Canada and was named senior vice president of Amgen International Commercial Operations. In 2009, he assumed additional responsibility for commercializing Amgen products in Japan. In May 2012 he became senior vice president, U.S. Commercial Operations.

Hoffmann has a wealth of international management experience gained over 25 years in the pharmaceutical industry. Before joining Amgen, he was chief executive of Lilly Deutschland GmbH global marketing. He has also held positions at Lilly as president, Latin America Area, general manager in South Africa and Sub-Saharan Africa, and numerous global and regional marketing assignments.

He received an MA in English from the University of Koeln in Koeln, Germany, and an MS degree in kinesiology from the Deutsche Sporthochschule, also in Koeln. Hoffmann also received an MBA from the University of North Carolina's Kenan-Flagler Business School in the United States.

Hoffmann is fluent in German and English and conversant in French and Spanish.

Dr. Harper joined Amgen in 2002 as vice president, Development, and has held several leadership roles, including heading the establishment of Amgen's Medical Sciences capability, a translational medicine group focused on biomarker discovery, development, and integration into early phase clinical studies. Dr. Harper served as vice president of Global Regulatory Affairs and Safety before assuming the role of senior vice president of Global Development and Corporate Chief Medical Officer. He became executive vice president, Research and Development in February 2012.

Prior to joining Amgen, Dr. Harper was senior director of clinical genomics at Merck Research Laboratories. He attended medical school at the University of California at San Francisco, completed internal medicine and gastroenterology training at the Massachusetts General Hospital, and was a postdoctoral fellow in the laboratory of Phillip A. Sharp at the Massachusetts Institute of Technology.

Laura Hamill is senior vice president, Regional General Manager, responsible for commercial operations in more than 35 countries, including Brazil, Colombia, Canada, Mexico, South Africa, and Turkey, as well as the Middle East. Laura joined Amgen in 2002 and became vice president, general manager of the Inflammation Business Unit in 2004. In 2007, she moved to Amgen’s international headquarters in Switzerland as the vice president, International Marketing and Business Operations. In 2009, Laura returned to the United States as vice president and general manager, Corporate Accounts. In 2011, she became vice president, general manager of the Commercial Operations Business Unit and then served as vice president, LACAN Regional General Manager.

With more than 25 years’ experience in the biotechnology and pharmaceutical industry, Laura has held a variety of roles within the areas of advertising, brand management, business analysis and strategic planning, general management and sales. Prior to joining Amgen, she held positions at Hoffmann La-Roche, Klemtner Advertising and Immunex.

Laura received a degree in Business Administration with an emphasis in Marketing from the University of Arizona. She is a board member of the Amgen Foundation and the executive leader of the Amgen’s Senior Women’s Advisory Council. Laura also is the Chair of the Pharma Latin America Regional Council, a member of the National Women’s Association, and member of the Women Business Leaders in Healthcare.

Dr. Steven K. Galson, senior vice president, Global Regulatory Affairs and Safety, joined Amgen in 2010 as vice president, Global Regulatory Affairs.

Prior to Amgen, Galson was senior vice president for Civilian Health Operations and chief health scientist at Science Applications International Corporation. Galson spent more than 20 years in government service, including two years as acting Surgeon General of the United States. Previously, he served as director of the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER), where he provided leadership for the center’s broad national and international programs in pharmaceutical regulation.

Galson began his Public Health Service (PHS) career as an epidemiological investigator at the Centers for Disease Control and Prevention (CDC) after completing a residency in internal medicine at the Hospitals of the Medical College of Pennsylvania. He also held senior-level positions at the Environmental Protection Agency (EPA); the Department of Energy, where he was chief medical officer; and the Department of Health and Human Services. Prior to his arrival at the FDA, Galson was director of the EPA’s Office of Science Coordination and Policy, Office of Prevention, Pesticides and Toxic Substances.

Galson holds a B.S. from Stony Brook University, an M.D. from Mt. Sinai School of Medicine, and an M.P.H. from the Harvard School of Public Health.

Dr. Paul R. Eisenberg is senior vice president, Global Medical and Chief Medical Officer, overseeing global medical and scientific affairs. Eisenberg joined Amgen in 2005 as vice president of Global Safety and was subsequently promoted to senior vice president of Global Regulatory Affairs and Safety. Since 2014 he has been responsible for Amgen’s Global Medical Affairs organization and the Chief Medical Officer.

Prior to Amgen, Eisenberg held several leadership roles at Lilly R&D in the cardiovascular, critical care, and inflammation therapeutic areas, in cardiovascular research and clinical investigation, and in global product safety.

Eisenberg received his M.D. from New York Medical College and his master’s of public health degree in tropical medicine from the Tulane University School of Public Health. He was professor of medicine at Washington University in St. Louis and director of cardiac intensive care at Barnes Hospital. During his 18-year academic career he was focused on basic and clinical research in cardiovascular disease and thrombosis.

Eisenberg has led the development and registration of multiple New Molecular Entities (NMEs) in cardiovascular and critical care, and he has also led the global registration of all Amgen products from 2007 to 2014. In addition, he has extensive experience in global safety and risk management programs.